Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in Elderly Patients with EGFR-mutated NSCLC
NCT02514174Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2015
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Participants Reporting an Adverse Event (AE) Leading to Dose Reduction of Afatinib up to 1085 days. Started Aug 2015; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02514174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02514174.